Work

477a A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMISUC, COHORT 1

Year: 2023

Type: article

Source: Gastroenterology

DOI: 10.1016/s0016-5085(23)04753-4

Authors: Bruce E. Sands, Laurent Peyrin-Biroulet, Silvio Danese, David T. Rubin, Severine Vermeire, Christopher Ma, Timothy Ritter, Remo Panaccione, Brian G. Feagan, Dermot P.B. Mcgovern, Olivier Laurent, Allison Luo, Deanna D. Nguyen, JD Lu, Anna Wiechowska-Kozlowska, Jaroslaw Leszczyszyn, Radoslaw Kempinski, Jaroslaw Kierkus, Stephan Targan

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4383378608

FWCI: 0.166

Cites:

Cited by: 1

Related to: 10